Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer)

Inclusion criteria:

• Is male or nonpregnant, nonlactating female
• Has been diagnosed with current severe NIPPU
• Has active disease at the Baseline Visit as defined by the presence of at least 1 ofthe following parameters in at least one eye despite at least 2 weeks of maintenancetherapy with oral prednisone (or oral corticosteroid equivalent):

1. Has active, inflammatory, chorioretinal and/or inflammatory retinal vascularlesion
2. Has ≥ 2+ anterior chamber cells [Standardization of Uveitis Nomenclature (SUN)criteria]
3. Has ≥ 1.5+ vitreous haze

• Is willing to taper current doses of corticosteroid and immunomodulatory therapy tothe minimum effective dose during the study.
• If under treatment with any immunosuppressants, immunomodulators, or biologic agentsfor a comorbid condition, has been on a stable dose for 2 weeks before screening

Exclusion criteria:

• Has proliferative or severe nonproliferative diabetic retinopathy, clinicallysignificant macular edema due to diabetic retinopathy, neovascular/wet age-relatedmacular degeneration, abnormality of vitreoretinal interface with the potential formacular structural damage independent of the inflammatory process or severe vitreoushaze that precludes visualization of the fundus at the Baseline Visit
• Has Type 1 or Type 2 diabetes mellitus, tuberculosis, history of hepatitis, pepticulcer, active infection, or any contraindication for treatment with Acthar Gel